From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma

被引：23

作者：

Anker, Jonathan ^{[1
]}

Miller, Justin ^{[2
]}

Taylor, Nicole ^{[2
]}

Kyprianou, Natasha ^{[3
,4
,5
]}

Tsao, Che-Kai ^{[2
,3
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Internal Med, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Pathol & Mol & Cell Based Med, New York, NY 10029 USA

[5] Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA

来源：

CELLS | 2021年 / 10卷 / 11期

关键词：

renal cell carcinoma; tumor microenvironment; immunology; immunotherapy; REGULATORY T-CELLS; PHASE I/II TRIAL; PATIENTS PTS; CHECKPOINT INHIBITORS; ADJUVANT SUNITINIB; SUPPRESSOR-CELLS; 1ST-LINE THERAPY; PROGNOSTIC VALUE; CTLA-4; BLOCKADE; DOSE-ESCALATION;

D O I：

10.3390/cells10113231

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subset of patients, many combination-based approaches have led to improved outcomes. The success of such approaches is a direct result of the tumor immunology knowledge accrued regarding the RCC microenvironment, which, while highly immunogenic, demonstrates many unique characteristics. Ongoing translational work has elucidated some of the mechanisms of response, as well as primary and secondary resistance, to immunotherapy. Here, we provide a comprehensive review of the RCC immunophenotype with a specific focus on how preclinical and clinical data are shaping the future of immunotherapy.

引用

页数：31

共 213 条

[71] Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial [J].

Haas, Naomi B. ;

Manola, Judith ;

Uzzo, Robert G. ;

Flaherty, Keith T. ;

Wood, Christopher G. ;

Kane, Christopher ;

Jewett, Michael ;

Dutcher, Janice P. ;

Atkins, Michael B. ;

Pins, Michael ;

Wilding, George ;

Cella, David ;

Wagner, Lynne ;

Matin, Surena ;

Kuzel, Timothy M. ;

Sexton, Wade J. ;

Wong, Yu-Ning ;

Choueiri, Toni K. ;

Pili, Roberto ;

Puzanov, Igor ;

Kohli, Manish ;

Stadler, Walter ;

Carducci, Michael ;

Coomes, Robert ;

DiPaola, Robert S. .

LANCET, 2016, 387 (10032) :2008-2016

[72] Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial [J].

Hakimi, A. Ari ;

Voss, Martin H. ;

Kuo, Fengshen ;

Sanchez, Alejandro ;

Liu, Ming ;

Nixon, Briana G. ;

Vuong, Lynda ;

Ostrovnaya, Irina ;

Chen, Ying-Bei ;

Reuter, Victor ;

Riaz, Nadeem ;

Cheng, Yuan ;

Patel, Parul ;

Marker, Mahtab ;

Reising, Albert ;

Li, Ming O. ;

Chan, Timothy A. ;

Motzer, Robert J. .

CANCER DISCOVERY, 2019, 9 (04) :510-525

[73]

Han YY, 2020, AM J CANCER RES, V10, P727

[74] A Phase I/II, open-label, two part study of GSK3359609 in combination with tremelimumab in participants with selected, advanced solid tumors [J].

Hansen, Aaron ;

Abdul-Karim, Raghad ;

Rizvi, Naiyer ;

Rischen, Danny ;

Hilton, John ;

Li, Zujun ;

Ott, Patrick ;

Karpinich-Fedoriw, Natalie ;

Yadavilli, Sapna ;

Wang, Xiaowei ;

Adams, Laurel ;

Wyres, Melody ;

Ferte, Charles ;

Ballas, Marc ;

Hoos, Axel ;

Zandberg, Daniel .

CANCER RESEARCH, 2019, 79 (13)

[75] Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer [J].

Hartman, Tiffiney R. ;

Demidova, Elena, V ;

Lesh, Randy W. ;

Hoang, Lily ;

Richardson, Marcy ;

Forman, Andrea ;

Kessler, Lisa ;

Speare, Virginia ;

Golemis, Erica A. ;

Hall, Michael J. ;

Daly, Mary B. ;

Arora, Sanjeevani .

SCIENTIFIC REPORTS, 2020, 10 (01)

[76] Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. [J].

Hong, David S. ;

Schoffski, Patrick ;

Calvo, Aitana ;

Sarantopoulos, John ;

De Olza, Maria Ochoa ;

Carvajal, Richard D. ;

Prawira, Amy ;

Kyi, Chrisann ;

Esaki, Taito ;

Akerley, Wallace L. ;

De Braud, Filippo G. ;

Hui, Rina ;

Zhang, Tian ;

Soo, Ross A. ;

Maur, Michela ;

Weickhardt, Andrew James ;

Chowdhury, Niladri Roy ;

Sabatos-Peyton, Catherine ;

Kwak, Eunice Lee ;

Tan, Daniel Shao-Weng .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[77] Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1 ) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment [J].

Hong, Xin ;

Wang, Xiaofeng ;

Wang, Tian ;

Zhang, Xu .

MEDICAL SCIENCE MONITOR, 2018, 24 :6861-6872

[78] Renal cell carcinoma [J].

Hsieh, James J. ;

Purdue, Mark P. ;

Signoretti, Sabina ;

Swanton, Charles ;

Albiges, Laurence ;

Schmidinger, Manuela ;

Heng, Daniel Y. ;

Larkin, James ;

Ficarra, Vincenzo .

NATURE REVIEWS DISEASE PRIMERS, 2017, 3

[79] Patients with sarcomatoid renal cell carcinoma-re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors [J].

Iacovelli, Roberto ;

Ciccarese, Chiara ;

Bria, Emilio ;

Bracarda, Sergio ;

Porta, Camillo ;

Procopio, Giuseppe ;

Tortora, Giampaolo .

EUROPEAN JOURNAL OF CANCER, 2020, 136 :195-203

[80] Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types [J].

Iglesia, Michael D. ;

Parker, Joel S. ;

Hoadley, Katherine A. ;

Serody, Jonathan S. ;

Perou, Charles M. ;

Vincent, Benjamin G. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11)

← 3 4 5 6 7 8 9 10 11 12 →